FOIU 2018: Prostate Sparing Cystectomy: Functional and Oncological Results

Tel-Aviv, Israel (UroToday.com) Jehonathan Pinthus, MD, gave an overview of the novel procedure of prostate capsule sparing radical cystectomy. Pinthus began his talk by stating that functional outcome must be weighed against any risk for an oncologic outcome. In fact, when performing a prostate capsule sparing radical cystectomy, we are worried about missing urothelial carcinoma in the prostate capsule, and missing prostate cancer (PC).

FOIU 2018: Statin Use in Prostate Cancer

Tel-Aviv, Israel (UroToday.com) Ilan Leibovitch, MD gave an overview on statin use in prostate cancer (PC). HMG-CoA reductase is a rate-limiting enzyme for cholesterol synthesis in the liver. Statins inhibit this enzyme. Statins are widely prescribed in the primary treatment of hypercholesterolemia and cardiovascular disease (CVD). They are among the most widely used drugs with over 24,000,000 adult users in the US alone. There is a plethora of evidence that statins prevent carcinogenesis (prostate, colorectal, lung and breast).

FOIU 2018: Agonists vs. Antagonists: Should Antagonists be the Primary Choice for ADT? - YES

Tel-Aviv, Israel (UroToday.com) David Margel, MD debated for the usage of antagonists as the primary choice for androgen deprivation therapy (ADT). GnRH antagonists have several potential advantages over agonists:

FOIU 2018: Agonists vs. Antagonists: Should Antagonists be the Primary Choice for ADT? - NO

Tel-Aviv, Israel (UroToday.com) Igor Tsaur, MD debated against the usage of LHRH antagonists as the primary form of androgen deprivation therapy (ADT). LHRH agonists have an increased risk for cardiovascular disease (CVD), diabetes, myocardial infarction and sudden death (Table 1). The different mechanisms of action of agonists and antagonists are demonstrated in figure 1. 

FOIU 2018: Intermittent vs. Continuous ADT

Tel-Aviv, Israel (UroToday.com) Laurence Klotz, MD gave a presentation on intermittent androgen deprivation therapy (IADT) and its association with cardiovascular disease (CVD). He began stating the many advantages of IADT:

FOIU 2018: Is there a "Cardio-friendly" ADT?

Tel-Aviv, Israel (UroToday.com) Bertrand Tombal, MD discussed whether there is a cardio-friendly androgen deprivation therapy (ADT). GnRH agonists are known to be associated with short-term increased risk of cardiovascular disease (CVD), especially in men with the pre-existing disease. Additionally, all men undergo metabolic changes with time. There has been published data showing a lower risk for degarelix when compared to agonists for CVD in patients with a CVD history (4.5% vs. 9.4%). 1

FOIU 2018: Epidemiology: The RADICAL PC Trial

Tel-Aviv, Israel (UroToday.com) Jehonathan Pinthus, MD presented the RADICAL PC trial and elaborated on the correlation of prostate cancer (PC) to cardiovascular disease (CVD). It is known that PC patients are at risk for CVD.1 Patients are deemed to be high-risk if they have a global risk estimate for severe CVD events with a rate of more than 2% per year. This risk increases significantly if patients are treated with hormonal therapy (Table 1).1